MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565347 | Name: Rifamycin SV

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rifamycin is a natural antibiotic which inhibits prokaryotic DNA-dependent RNA synthesis and protein synthesis, thereby blocking RNA-polymerase transcription initiation.

Chemical Structure

Rifamycin SV
Rifamycin SV
CAS#6998-60-3 (free acid)

Theoretical Analysis

MedKoo Cat#: 565347

Name: Rifamycin SV

CAS#: 6998-60-3 (free acid)

Chemical Formula: C37H47NO12

Exact Mass: 697.3098

Molecular Weight: 697.78

Elemental Analysis: C, 63.69; H, 6.79; N, 2.01; O, 27.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
6998-60-3 (free acid) 15105-92-7 (sodium)
Synonym
Rifamycin; CB-01-11; CB01-11; CB 01-11; CB-0111; CB0111; CB 0111; NSC 133100; Rifamicine SV; Rifamycin SV; Rifocin; Rifocyn; Rifomycin SV; Aemcolo,
IUPAC/Chemical Name
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate
InChi Key
HJYYPODYNSCCOU-ODRIEIDWSA-N
InChi Code
InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
SMILES Code
CC(O[C@@H]([C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)\C(N1)=O)[C@H](C)[C@@H](OC)/C=C/O[C@](O2)(C)C(C3=C2C(C)=C(O)C4=C3C(O)=CC1=C4O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 697.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548896/ PubMed PMID: 31644203. 2: Hoy SM. Rifamycin SV MMX(®): A Review in the Treatment of Traveller's Diarrhoea. Clin Drug Investig. 2019 Jul;39(7):691-697. doi: 10.1007/s40261-019-00808-2. Review. Erratum in: Clin Drug Investig. 2019 Jun 20;:. PubMed PMID: 31172447. 3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK540689/ PubMed PMID: 31038854. 4: Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review. PubMed PMID: 28803492. 5: Lin SW, Lin CJ, Yang JC. Rifamycin SV MMX for the treatment of traveler's diarrhea. Expert Opin Pharmacother. 2017 Aug;18(12):1269-1277. doi: 10.1080/14656566.2017.1353079. Epub 2017 Jul 27. Review. PubMed PMID: 28697313. 6: Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol. 2018 Jan;218(1):88-97.e14. doi: 10.1016/j.ajog.2017.07.003. Epub 2017 Jul 8. Review. PubMed PMID: 28694152. 7: Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemant M, Hesseling A, Schaaf HS. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opin Pharmacother. 2017 Apr;18(6):589-598. doi: 10.1080/14656566.2017.1309023. Epub 2017 Mar 27. Review. PubMed PMID: 28346018. 8: Rockwood N, Abdullahi LH, Wilkinson RJ, Meintjes G. Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis. PLoS One. 2015 Sep 25;10(9):e0139017. doi: 10.1371/journal.pone.0139017. eCollection 2015. Review. Erratum in: PLoS One. 2015;10(11):e0142276. PubMed PMID: 26406228; PubMed Central PMCID: PMC4583446. 9: Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun;42(6):827-35. doi: 10.1345/aph.1K675. Epub 2008 Apr 22. Review. PubMed PMID: 18430792. 10: Wallis RS, Weyer K, Fourie PB. Acquired rifamycin resistance: pharmacology and biology. Expert Rev Anti Infect Ther. 2008 Apr;6(2):223-30. doi: 10.1586/14787210.6.2.223. Review. PubMed PMID: 18380604. 11: Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005 Apr;3(2):201-11. Review. PubMed PMID: 15918778. 12: Pelosini I, Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy. 2005;51 Suppl 1:122-30. Review. PubMed PMID: 15855757. 13: Floss HG, Yu TW. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005 Feb;105(2):621-32. Review. PubMed PMID: 15700959. 14: Lounis N, Roscigno G. In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des. 2004;10(26):3229-38. Review. PubMed PMID: 15544512. 15: Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327-41. Review. PubMed PMID: 11432536. 16: Floss HG, Yu TW. Lessons from the rifamycin biosynthetic gene cluster. Curr Opin Chem Biol. 1999 Oct;3(5):592-7. Review. PubMed PMID: 10508670. 17: Hidaka T. [Current status and perspectives on the development of rifamycin derivative antibiotics]. Kekkaku. 1999 Jan;74(1):53-61. Review. Japanese. PubMed PMID: 10067056. 18: Caruso I. Twenty years of experience with intra-articular rifamycin for chronic arthritides. J Int Med Res. 1997 Nov-Dec;25(6):307-17. Review. PubMed PMID: 9427164. 19: Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol. 1996 Jan-Feb;147(1-2):48-52. Review. PubMed PMID: 8761722. 20: Chiao JS, Xia TH, Mei BG, Jin ZK, Gu WL. Rifamycin SV and related ansamycins. Biotechnology. 1995;28:477-98. Review. PubMed PMID: 8688635.